I've been watching ZLCS closely. It's quite interesting and I definitely remember ziconotide quite well. I would just caution your statement by saying that pain trials are notoriously difficult and ZLCS is running Phase 2a studies so no where near ACAD in terms of stage. Having said this, I like the management team, the concept, the science, the revenue generation and the potential. I personally am considering nibbling on ZLCS but am still in the due-diligence stage. I do think it's an interesting story though.
Now to ACAD.....Longs....can you believe we're here finally! I'm still holding the bulk of my shares. How are all of you doing? Congrats to you guys...we had a fun time talking when we were in the early days of this run and before.
I posted two weeks ago that ACAD would be at $25 ( a rather conservative estimate) last Friday and I was scoffed at as a shameless pumper. So I was a week off. This run is far from over. I really like all these small biopharma's being touted as the next ACAD. It's great . . . but, in reality ACAD is only a fraction of what it will ultimately become in the next 12-24 months. I am not looking for the next ACAD . . . I keep buying more ACAD as I am able. ACAD is the next ACAD in my books!
This is what people need to realize, and that is Zalicus is generating revenue. I find this to be one of the most important dynamics going forward. Below is a piece of this mornings new article.
"Not many biotechs trading under $3 generate any revenues. If Z160 is successful in clinical trials and matches gabapentin, or lyrica sales, it would easily justify a stock price over 20 times the current price. Analysts have estimated the market opportunity for Z160 to be anywhere from $500 million to $2.7 billion. Comparable to peak sales for gabapentin. Z160 could see significant off label usage being that it is a non-opioid with a superior side effect profile. The FDA has made a significant effort to approve drugs with less abuse potential which favors non-opioids such as Z160."
Sentiment: Strong Buy